We are live on ! Find out more
KLDO

Kaleido Biosciences, Inc. Common Stock
KLDO

Delisted

KLDO was delisted on the 14th of April, 2022.

Back to rankings

24 hedge funds and large institutions have $336M invested in Kaleido Biosciences, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
24
Holders Change
+24
Holders Change %
–
% of All Funds
0.52%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
24
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FP
Flagship Pioneering
Massachusetts
+$239M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$24.9M
3
HP
Harbourvest Partners
Massachusetts
+$16.1M
4
AG
Artal Group
Luxembourg
+$13M
5
PAI
Palo Alto Investors
California
+$11.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$252M +$239M +17,360,710 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$25.1M +$24.9M +1,809,083 New
HP
3
Harbourvest Partners
Massachusetts
$16.9M +$16.1M +1,167,166 New
AG
4
Artal Group
Luxembourg
$13.7M +$13M +947,419 New
PAI
5
Palo Alto Investors
California
$12.6M +$11.9M +866,666 New
Baillie Gifford & Co
6
Baillie Gifford & Co
United Kingdom
$6.38M +$6.06M +440,000 New
RSCM
7
Rock Springs Capital Management
Maryland
$1.45M +$1.38M +100,050 New
Victory Capital Management
8
Victory Capital Management
Texas
$1.39M +$1.32M +95,840 New
Millennium Management
9
Millennium Management
New York
$1.28M +$1.21M +88,109 New
KA
10
Kerrisdale Advisers
Florida
$1.05M +$999K +72,580 New
ACPU
11
Arrowgrass Capital Partners (US)
Delaware
$725K +$688K +50,000 New
MIM
12
Monashee Investment Management
Massachusetts
$725K +$688K +50,000 New
Goldman Sachs
13
Goldman Sachs
New York
$718K +$682K +49,525 New
DIM
14
DC Investments Management
Virginia
$611K +$580K +42,164 New
Norges Bank
15
Norges Bank
Norway
$580K +$551K +40,000 New
BCM
16
Barometer Capital Management
Ontario, Canada
$443K +$421K +30,573 New
BCM
17
BlueCrest Capital Management
Jersey
$165K +$157K +11,412 New
Barclays
18
Barclays
United Kingdom
$56K +$52.9K +3,847 New
Citigroup
19
Citigroup
New York
$35K +$32.8K +2,382 New
Bank of America
20
Bank of America
North Carolina
$34K +$32.4K +2,353 New
Morgan Stanley
21
Morgan Stanley
New York
$31K +$29K +2,110 New
FIA
22
FNY Investment Advisers
New York
$14K +$13.8K +1,000 New
CCA
23
Catalyst Capital Advisors
New York
$7K +$6.79K +493 New
JP Morgan Chase
24
JP Morgan Chase
New York
$4K +$4.13K +300 New

KLDO Hedge Fund Activity: Q1 2019 in Review

24 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q1 2019, worth a combined $336M.

Buyers outnumbered sellers: 24 funds opened new KLDO positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Flagship Pioneering, opening a new position worth an estimated $239M.

  • 24 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q1 2019, up from 0 in Q4 2018.
  • Funds reported $336M of Kaleido Biosciences, Inc. Common Stock stock for Q1 2019.
  • 24 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q1 2019 and 0 closed out, a net change of +24 holders.
  • The largest Kaleido Biosciences, Inc. Common Stock buyer in Q1 2019 was Flagship Pioneering, an estimated $239M added.

Based on aggregated 13F filings for Q1 2019.